Business Context and Reporting Period
Company: 60 Degrees Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 3, 2026
Reporting Period: Single event disclosure dated June 3, 2026.
Business Overview: The registrant is an emerging growth company developing pharmaceutical treatments, specifically focusing on tafenoquine for severe babesiosis.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a disclosure of a specific corporate event and does not contain financial statements or quantitative financial data.
Material Changes
No material changes to financial position or operations are reported in this filing. The document discloses a strategic intent regarding future regulatory applications rather than a change in current financial status.
Guidance, Outlook, and Risks
- Regulatory Strategy: The Company intends to submit an application for a Commissioner's National Priority Review Voucher if interim and/or final analysis of its randomized, placebo-controlled trial of tafenoquine in patients hospitalized with severe babesiosis supports moving forward with a New Drug Application (NDA).
- Timeline: The potential NDA submission to the U.S. Food and Drug Administration (FDA) is targeted before the end of the first quarter of 2028.
- Forward-Looking Statements: The Company explicitly states that expectations regarding the trial, NDA submission, and voucher application are forward-looking and subject to risks.
- Risks and Uncertainties: Key risks include the outcome of clinical development, interactions with regulatory authorities, and other factors that could cause actual results to differ materially from anticipated plans.
Investor Verification Checklist
- Verify the status and results of the randomized, placebo-controlled trial of tafenoquine for severe babesiosis.
- Confirm the Company's cash runway and liquidity position to support operations through the potential Q1 2028 NDA submission timeline.
- Review the "Risk Factors" section in the most recent Form 10-K and Form 10-Q for detailed disclosures on clinical trial risks.
- Monitor future communications regarding the decision to submit the Commissioner's National Priority Review Voucher application.